Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-97,788
Closed -$4M 684
2024
Q3
$4M Buy
+97,788
New +$4M 0.09% 170
2024
Q2
Sell
-1,651,754
Closed -$70.8M 551
2024
Q1
$70.8M Buy
1,651,754
+244,075
+17% +$10.1M 1.59% 19
2023
Q4
$52.2M Sell
1,407,679
-215,881
-13% -$7.75M 1.32% 21
2023
Q3
$58.9M Sell
1,623,560
-144,646
-8% -$5.13M 1.5% 20
2023
Q2
$63M Buy
1,768,206
+252,813
+17% +$9.07M 1.38% 20
2023
Q1
$53.9M Sell
1,515,393
-199,778
-12% -$6.99M 1.05% 27
2022
Q4
$60.3M Buy
1,715,171
+427,563
+33% +$14.2M 1.02% 18
2022
Q3
$37.9M Sell
1,287,608
-5,670
-0.4% -$215K 0.53% 39
2022
Q2
$70.4K Buy
1,293,278
+755,561
+141% +$41.7M 0.73% 26
2022
Q1
$29.3M Buy
+537,717
New +$29.2M 0.31% 53

Other funds holding GSK

Magnetar Financial's GSK Position: Q4 2024 in Review

Magnetar Financial sold out of GSK (GSK) in Q4 2024, closing a stake of 97,788 shares — an estimated $4M sold.

Magnetar Financial first reported a position in GSK in Q1 2022 and held it in 10 quarters. The position peaked at $70.8M in Q1 2024. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

  • Magnetar Financial reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
  • Magnetar Financial sold 97,788 GSK shares in Q4 2024, an estimated $4M.
  • Magnetar Financial first reported a position in GSK in Q1 2022 and held it in 10 quarters.
  • Magnetar Financial's GSK position peaked at $70.8M in Q1 2024.
  • 848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Magnetar Financial's 13F filing for Q4 2024, filed 11 Feb 2025.